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 HIGHLIGHTS  
 The antiEpEX-scFv was successfully expressed in E. coli Rosetta™(DE3) strain. 
 The highest concentration of protein was obtained with 0.5 mM IPTG at 30°C. 










 The EpCAM (epithelial cell adhesion molecule) is a cell surface antigen over 
expressed in many types of epithelial cell cancers including colon, stomach, 
pancreas, lung, ovarian, and breast. So, it can be an attractive target for active and 
passive immunotherapy of cancers. ScFv (single chain fragment variable) 
fragment is a class of engineered antibodies in which the genes coding for the 
heavy (VH) and light chains (VL) of an immunoglobulin have been linked with a 
short flexible peptide linker. Inexpensive media, rapid growth rates, and 
relatively minimal laboratory set up make Escherichia coli (E. coli) a suitable 
host for expression of a large variety of recombinant proteins. Here, we assessed 
the effect of cultivation conditions on the level of expressed scFv against 
extracellular domain of EpCAM (EpEX) in E. coli. pET22b-antiEpEX-scFv was 
transformed into prepared E. coli Rosetta™(DE3) competent cells. To evaluate 
the effect of cultivation conditions on protein expression level, three factors of 
incubation temperature (25, 30, 37°C), the IPTG (isopropyl-β-D-thiogalactoside) 
concentration (0.1, 0.25, 0.5, 1 mM), and induction duration (3, 5, 7, 18 h) were 
considered. SDS-PAGE and western blot analysis demonstrated an estimated  
30 kDa-size protein band which was related to the recombinant scFv expressed in 
E. coli Rosetta™(DE3) strain. At optimal condition (5 h after induction with 0.5 
mM IPTG at 25 °C), the final production yield of the antiEpEX-scFv was 403.29 ± 
87.50 μg/mL. Our results provide a foundation for the development of scFv-based 
drugs’ production as effective therapeutic agents in cancers with epithelial origin.  
 
Introduction  
The epithelial cell adhesion molecule (EpCAM) is a  
40-kDa, transmembrane, 314-amino acid-long glycoprotein 
(Karabulut et al., 2014). In addition to cell migration, it 
is involved in cell adhesion, proliferation, and 
differentiation. However, its function is still largely 
unknown (Tas et al., 2014). Although EpCAM is 
overexpressed in various epithelial tumors such as 
colon, breast, rectum, biliary tract, stomach, prostate, 
pancreas, and hepatocellular, it is also expressed in the 
corresponding normal epithelia. However, in normal 
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what was found in tumor cells (Schmetzer et al., 2012). 
So, EpCAM can be potentially utilized as a suitable 
target for passive immunotherapy with monoclonal 
antibodies (mAb). Since the 1980s frequent studies were 
done to investigate the effectiveness of anti-EpCAM 
antibodies based targeted therapy. MAb17-1A, an anti-
EpCAM monoclonal antibody with a low affinity was 
successfully used for colon and breast carcinoma 
therapy in Germany (Kirchner et al., 2002). Moreover, a 
bispecific scFv against EpCAM named CD3/17-1A 
showed an effective in vitro cytotoxicity to tumor cells 
(Mack et al., 1995). Finally, for the treatment of the 
patients with malignant ascites, European Union has 
approved catumaxomab which is a trifunctional 
monoclonal antibody against EpCAM/CD3 (Burges et 
al., 2007). Recent advances in recombinant antibody 
technology could facilitate designing and producing a 
wide variety of engineered antibody molecules including 
Fv fragments, Fab fragments, and scFv (single chain 
fragment variable) fragments in which the genes coding 
for VH and VL chains of an immunoglobulin molecule 
have been linked with a disulfide bond or a short 
flexible peptide linker. Better tumor penetration, lower 
retention times in nontarget tissues, more rapid blood 
clearance, and reduced immunogenicity are some of the 
several advantages of these minimized antibodies 
compared with the parental ones (Wang et al., 2015). 
Previously, scFv fragments were proved to be effective 
in treatment of the cancers in which the EpCAM 
receptor was overexpressed. Bispecific and fully 
humanized scFv fusion proteins against extracellular 
domain of EpCAM (EpEX) have been investigated in 
preclinical studies and clinical trials (Brischwein et al., 
2006). Moreover, suitable in vitro antitumor activities 
were reported for several anti-EpCAM immunotoxins 
previously (Di Paolo et al., 2003).  
Recently, the genes encoding several scFv fragments 
have been successfully cloned and expressed in bacteria, 
yeast, plant, and also mammalian cells. Inexpensive 
media, rapid growth rates, and relatively minimal 
laboratory set up make E. coli a suitable host for 
expression of a large variety of recombinant proteins 
(Wang et al., 2015, Agha Amiri et al,. 2017, Slouka et 
al., 2019). Moreover, using this favorable bacterial host, 
high antibody titers have been obtained (up to 2 g/L) 
(Chen et al., 2004).  
Here, for the first time, a scFv from 4D5MOC-B 
humanized antiEpEX monoclonal antibody was 
expressed in E. coli Rosetta™(DE3) strain. The effect of 
temperature and IPTG concentration on the level of 
expressed antiEpEX-scFv was also evaluated. 
Materials and Methods 
Materials  
Escherichia coli (DH5α) was used for plasmid 
preparation and E. coli Rosetta™(DE3) was used as a 
host for recombinant scFv expression (Pasteur institute 
of IRAN, Tehran, Iran). Luria–Bertani (LB) medium 
[0.5% (w/v) yeast extract, 1% (w/v) tryptone, and 1% 
(w/v) NaCl, pH 7.0] supplemented with the antibiotic 
ampicillin (100 μg/mL) was used for growing the E. coli 
strains. Restriction endonucleases and T4 DNA ligase 
were purchased from Thermo Fisher Scientific (USA). 
Standard commercial sources have provided all used 
reagents and chemicals. 
The antiEPEX -scFv expression 
E. coli strain of Rosetta™(DE3) was transformed with 
previously developed pET22b vector harbouring the 
codon optimized antiEpEX-ScFv gene (pET22b-
antiEpEX-scFv). For cultivation of host harboring 
pET22b-antiEpEX-scFv, a single colony was inoculated 
into 3 mL of Luria–Bertani (LB) broth containing 100 
μg/mL ampicillin. After overnight shaking at 37 °C, the 
culture was transferred to LB medium containing 100 
μg/mL ampicillin at a ratio of 1∶10. Once the cell density 
(OD) reached 0.7–0.9, 1mM IPTG (Sinaclon, Iran) was 
added to the culture which was shaken for another 3, 5, 
7, and 18 h under the same conditions.  
Effects of cultivation conditions on antiEpEX-scFv 
expression 
To evaluate the effect of culture condition on protein 
expression level, three factors of incubation temperature 
(25, 30, 37°C), the inducer concentration (0.1, 0.2, 0.5, 1 
mM) and induction duration (3, 5, 7, 18 h) were 
considered. The cell pellets were harvested by 
centrifugation at 10000 rpm for 5 min. 
SDS-PAGE and western blot analysis 
The expression of recombinant protein was assessed by 
standard SDS-PAGE method. A c-terminal poly histidine 
tag was employed for detection of recombinant protein 
in designed construct. For western blotting, after 
separation by 12% SDS-PAGE, the bacterial lysates 
were transferred to PVDF membrane. 2% bovine serum 
albumin (BSA) in phosphate-buffered saline with 0.1% 
Tween 20 (PBST) was used to block the transferred 
membrane. 1/10000 dilution of anti-his tag polyclonal 
antibody was used as the primary antibody (Sigma, UK). 
After washing, membrane was incubated in a 1.5/10000 
dilution of anti-mouse HRP conjugated immunoglobulin 
(Sigma, UK) as the secondary one. The blot was 
developed using 3, 3'-diaminobenzidine (DAB) substrate. 
Utilizing TL120 software (Nonlinear Inc, Durham, USA), 
the protein expression level was assessed by densitometry 
analysis of poly acrylamide gels. 
Determination of protein concentration 
The total protein concentrations were determined via the 
bicinchoninic acid (BCA) assay and BSA was used as 
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standard (Takara, Japan). For sample preparation, the 
total bacterial pellets were lysed in lysis buffer (100 mM 
NaH2PO4, 10 mM urea, pH= 8). The standard curve 
was generated based on concentrations of BSA standard 
samples. The concentration of the total protein was 
determined using the standard curve as a reference. 
Total protein samples were also electrophoresed on a 
12% SDS-PAGE gel. The band intensity of recombinant 
protein was analyzed using TL120 software (Nonlinear 
Inc, Durham NC, USA). Based on estimated intensity, 
TL120 calculates the quantity of recombinant protein as 
a percentage of total protein. According to total protein 
concentrations obtained from BCA assay and percentage 
of recombinant protein obtained from TL120 analysis, 
the concentration of recombinant protein can be 
calculated. 
Results and Discussion 
Expression and detection of antiEPEX-scFv protein 
The pET22b vector harboring the codon optimized 
antiEPEX-ScFv gene (pET22b-antiEPEX-scFv) was 
transformed into Rosetta™(DE3) competent cells. When 
recombinant proteins are expressed in E. coli, translation 
may be hampered because of shortage or lacking for one 
or more tRNAs. So, two strategies can be considered to 
improve heterologous protein expression in E. coli; 
codon optimization in target gene and utilization of 
engineered hosts which can supply the rare tRNAs 
during the expression (Kong and Guo, 2014). Previously 
published data has shown a significant promotion in 
protein level of eukaryotic genes expressed in E. coli 
after codon-optimization. For example, after codon 
optimization, higher amount of recombinant fGH was 
achieved in E. coli (Choi and Geletu, 2018). 
Overcoming this disparity, numerous bacterial strains 
such as Rosetta™(DE3) has been also developed. E. coli 
strain Rosetta™(DE3) which carries tRNA for rare 
codons including AUA, AGG, CUA, AGA, GGA, and 
CCC has been successfully employed by several studies. 
For example, when human β-defensin 2 (hBD2) gene 
was expressed in Rosetta™(DE3) strain, a nine-fold 
increase has been reported in its expression level by 
Peng et al. (2004). Introducing T7 polymerase encoding 
gene in E. coli strain Rosetta™(DE3) genome makes 
this host suitable for expression of genes cloned in pET 
vectors with T7 promoter. Here, the antiEPEX-scFv 
gene was expressed in pET22b (+) vector under the 
strong T7 promoter system in E. coli Rosetta™(DE3). 
Up to now, E. coli Rosetta™(DE3) was successfully 
utilized to improve expression of recombinant scFvs. As 
an example, the engineered scFv-mms13 fusion protein 
was successfully expressed in this expression host 
(Kong et al., 2015). 
After cultivation at the 1 mM IPTG at 37°C, the 
bacterial cells were lysed and analyzed via SDS PAGE. 
Compared to the negative control, the protein band was 
detected at the theoretically expected molecular weight 
(30 kDa) (Fig. 1).  
 
Figure 1. Expression analysis of the antiEPEX-scFv protein using SDS-PAGE. The expression level of target protein was examined in three 
clones. Proteins were separated on a 12 % SDS-PAGE gel and visualized by coomassie brilliant blue R250 staining. Total protein was extracted 
from E. coli Rosetta™(DE3) containing pET22b-antiEpEX-scFv plasmid before induction (U) and after induction with 1 mM IPTG for 3h, 5h, 7h 
and 18h respectively at 37 °C (M: protein marker). Control is cells transformed with pET22b. 





The expression level of target protein was examined 
in three clones. By screening various incubation times 
(3, 5, 7, 18h), the highest protein expression level was 
obtained at 5 h after induction in clone 3 (Fig. 1). As 
shown in fig. 1 D, based on densitometry analysis and 
BCA assay, maximum level of expressed recombinant 
scFv was estimated up to 194.45 μg/mL (at 5 h after 
induction) 223.13 μg/mL (at 18 h after induction) and 
243.09 μg/mL (at 5 h after induction) in three clones 
examined respectively. However, the expressed protein 
had a higher level (243.09 μg/mL) in clone 3 (Fig. 1 D). 
Using anti-his antibody, the western blotting analysis 
indicated that expressed antiEPEX-scFv was a his-
tagged fusion protein (Fig. 2).  
 
Figure 2. Western blotting analysis of the recombinant antiEPEX-scFv 
protein. Bacterial lysates  of E. coli Rosetta™(DE3) before (U) and 
after induction (In) were treated with the anti His monoclonal 
antibodies (M: pre-stained protein marker). The antiEPEX-scFv 
protein (30-kDa) is denoted. 
 
Effects of temperature and IPTG concentration on the 
expression level of antiEPEX-scFv  
The concentration of IPTG needs to be optimized 
because on the one hand, it has a determining role in 
protein expression level, but on the other hand, it causes 
serious harm to cell growth (Rasouli kery bozorg and 
Hashemi, 2019). In this study, the effect of different 
IPTG concentrations (0.1, 0.25, 0.5 or 1 mM) on 
expression level of recombinant protein was examined 
(Fig. 3). Moreover, based on many reports demonstrated 
that the growth temperature had the most serious impact 
on improving protein production in the E. coli B strains 
(Rasouli kery bozorg and Hashemi, 2019), here, the 
effect of different temperatures (25, 30, 37°C) on anti 
EpEX-scFv expression level was also evaluated. Based 
on densitometry analysis as well as BCA assay, the 
highest level of expressed antiEPEX-scFv was achieved 
by 0.5 mM IPTG induction at 25°C for 5 h (Fig. 4). As 
shown in fig. 4, the productivity of antiEPEX-scFv 
protein was decreased using higher IPTG concentration 
(1mM) at this temperature. In accordance with our 
results, Zheng et al. reported a significant decrease in the 
expression level of acetolactate synthase in E. coli when 
the IPTG concentration was more than 0.6 mM (Zheng 
et al., 2015). Similarly, in two previously published 
studies, an improved expression of recombinant form of 
one major mango allergen (rMan i 1) as well as 
recombinant pneumococcalsurface adhesin A (rPsaA) in 
E. coli was obtained when a low concentration of IPTG 
was used for induction (Larentis et al., 2011, Tsai et al., 
2017). The results obtained in our study also are in 
accordance with data reported by Lim et al. which 
demonstrated an inhibition in the expression of scFv 
against anti-exotoxin when more than 1 mM IPTG was 
used for induction (Lim et al., 2004). The IPTG toxic 
effect may be due to an induction of bacterial proteases 
which may degrade recombinant proteins. Proteases were 
also able to enhance metabolic load (Lim et al., 2004).  
 
Figure 3. The effects of IPTG concentration (mM) and incubation temperature on antiEPEX-scFv protein expression in E. coli Rosetta™(DE3). 
After separation on a 12 % SDSPAGE gel, protein bands were visualized by coomassie brilliant blue R250 staining. Protein expression was 
induced with different concentrations of IPTG (0.1, 0.25, 0.5, and 1 mM) at A and B: 25 °C, C and D: 30 °C, and E and F: 37 °C for 5 h. Lane M: 
protein marker. Lane U: bacterial culture before induction. The position of antiEPEX-scFv was indicated. 
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Figure 4. Comparison of the concentration of the expressed antiEPEX-scFv depending on different IPTG concentrations (mM) and incubation 
temperatures. Protein expression was induced with different IPTG concentrations (0.1, 0.25, 0.5, and 1 mM) at A: 25 °C, B: 30 °C, and C: 37 °C 
for 5 h. D: The maximum protein concentration obtained from A, B and C has been compared.  
 
The final yield of the recombinant protein can also 
be affected by temperature via influencing on mRNA 
expression rate, protein folding, aggregation, and 
secretion (Gupta and Shukla, 2016). Here, the maximum 
level of recombinant protein was attained at a low 
temperature of 25 °C (Fig. 3 and 4). This may be related 
to less activity of the proteases at lower temperatures. 
Our results are in good agreement with one report 
indicating that the highest amount of anti-thyroid 
stimulating hormone (TSH) scFv expression could be 
achieved after induction at 24 °C (Santala and 
Lamminmäki, 2004). Consistent with our results, based 
on the design of experiments approach, the optimum 
temperature for the expression of scFv against CD22 
conjugated with apoptin in E. coli BL21 (DE3) was also 
reported as low as 25 °C (Agha Amiri et al., 2017).  
Under the above optimal condition (cultivation at 25°C 
and 0.5 mM IPTG), a high percentage of the target 
protein was achieved in Rosetta™(DE3) (49% of the 
total protein). The volumetric productivity of protein 
reached 403.29 ± 87.50 mg/L (Fig. 4). Conclusively, 
although at lower temperature there was a general trend 
for less expression, the temperature effect on protein 
expression level was not as straightforward as expected. 
Conclusion 
In this study, for the first time, a scFv from 4D5MOC-B 
humanized antiEpEX monoclonal antibody was 
expressed in E. coli Rosetta™(DE3) strain. Moreover, 
here, the effect of cultivation conditions on recombinant 
antiEpEX-scFv expression level was evaluated. Based 
on the obtained results, at optimal condition (5 h after 
induction with 0.5 mM IPTG at 25 °C), the final 
production yield of the antiEpEX-scFv was 403.29 ± 
87.50 μg/mL which makes the subsequent in vitro 
functional trials and structural characterization possible. 
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